XML 42 R32.htm IDEA: XBRL DOCUMENT
v3.24.3

Segment Information (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2024
Segment Information |
Summary of results of operations by segment | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(In thousands) | ​ | ​ | ​ | Contract | ​ | Corporate | ​ | Total
Three Months Ended September 30, 2024 | ​ | Therapeutics | ​ | Research | ​ | and Other | ​ | Company
Revenue from external customers | ​ | $ | 3,701 | ​ | $ | 645 | ​ | $ | — | ​ | $ | 4,346
Intercompany revenue | ​ | ​ | — | ​ | ​ | 3,035 | ​ | ​ | (3,035) | ​ | ​ | —
Cost of revenue | ​ | ​ | — | ​ | ​ | 3,485 | ​ | ​ | (2,831) | ​ | ​ | 654
Research and development | ​ | ​ | 6,129 | ​ | ​ | — | ​ | ​ | (205) | ​ | ​ | 5,924
General and administrative | ​ | ​ | — | ​ | ​ | 905 | ​ | ​ | 4,748 | ​ | ​ | 5,653
Licensing | ​ | ​ | 1,754 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,754
Revaluation of contingent consideration | ​ | ​ | 800 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 800
Restructuring expense | ​ | ​ | 32 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 32
Loss from operations | ​ | $ | (5,014) | ​ | $ | (710) | ​ | $ | (4,747) | ​ | $ | (10,471)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(In thousands) | ​ | ​ | ​ | Contract | ​ | Corporate | ​ | Total
Three Months Ended September 30, 2023 | ​ | Therapeutics | ​ | Research | ​ | and Other | ​ | Company
Revenue from external customers | ​ | $ | 8,577 | ​ | $ | 705 | ​ | $ | — | ​ | $ | 9,282
Intercompany revenue | ​ | ​ | — | ​ | ​ | 4,112 | ​ | ​ | (4,112) | ​ | ​ | —
Cost of revenue | ​ | ​ | — | ​ | ​ | 4,726 | ​ | ​ | (3,878) | ​ | ​ | 848
Research and development | ​ | ​ | 24,110 | ​ | ​ | — | ​ | ​ | (234) | ​ | ​ | 23,876
General and administrative | ​ | ​ | — | ​ | ​ | 1,174 | ​ | ​ | 5,917 | ​ | ​ | 7,091
Licensing | ​ | ​ | 7,344 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 7,344
Revaluation of contingent consideration | ​ | ​ | 1,700 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,700
Loss from operations | ​ | $ | (24,577) | ​ | $ | (1,083) | ​ | $ | (5,917) | ​ | $ | (31,577)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(In thousands) | ​ | ​ | ​ | Contract | ​ | Corporate | ​ | Total
Nine Months Ended September 30, 2024 | ​ | Therapeutics | ​ | Research | ​ | and Other | ​ | Company
Revenue from external customers | ​ | $ | 7,583 | ​ | $ | 1,926 | ​ | $ | — | ​ | $ | 9,509
Intercompany revenue | ​ | ​ | — | ​ | ​ | 10,122 | ​ | ​ | (10,122) | ​ | ​ | —
Cost of revenue | ​ | ​ | — | ​ | ​ | 11,346 | ​ | ​ | (9,476) | ​ | ​ | 1,870
Research and development | ​ | ​ | 23,555 | ​ | ​ | — | ​ | ​ | (645) | ​ | ​ | 22,910
General and administrative | ​ | ​ | — | ​ | ​ | 3,033 | ​ | ​ | 13,184 | ​ | ​ | 16,217
Licensing | ​ | ​ | 4,070 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 4,070
Revaluation of contingent consideration | ​ | ​ | 3,800 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3,800
Restructuring expense | ​ | ​ | 1,650 | ​ | ​ | 217 | ​ | ​ | 1,032 | ​ | ​ | 2,899
Loss from operations | ​ | $ | (25,492) | ​ | $ | (2,548) | ​ | $ | (14,217) | ​ | $ | (42,257)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(In thousands) | ​ | ​ | ​ | Contract | ​ | Corporate | ​ | Total
Nine Months Ended September 30, 2023 | ​ | Therapeutics | ​ | Research | ​ | and Other | ​ | Company
Revenue from external customers | ​ | $ | 11,210 | ​ | $ | 2,469 | ​ | $ | — | ​ | $ | 13,679
Intercompany revenue | ​ | ​ | — | ​ | ​ | 12,122 | ​ | ​ | (12,122) | ​ | ​ | —
Cost of revenue | ​ | ​ | — | ​ | ​ | 14,068 | ​ | ​ | (11,370) | ​ | ​ | 2,698
Research and development | ​ | ​ | 72,490 | ​ | ​ | — | ​ | ​ | (752) | ​ | ​ | 71,738
General and administrative | ​ | ​ | — | ​ | ​ | 3,490 | ​ | ​ | 20,708 | ​ | ​ | 24,198
Licensing | ​ | ​ | 8,955 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 8,955
Revaluation of contingent consideration | ​ | ​ | (600) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (600)
Loss from operations | ​ | $ | (69,635) | ​ | $ | (2,967) | ​ | $ | (20,708) | ​ | $ | (93,310)
​

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration